Papers by Guoping Yang · AgingResearch.News

Cell Metabolism8 Oct
A triple-target drug cut body weight by up to 19.7% in a trial
Average body weight fell between 13.6% and 19.7% across drug doses compared with 2.0% on placebo over 24 weeks.Average body weight fell between 13.6% and 19.7% across drug doses compared with 2.0% on placebo over 24 weeks.
Randomised trial in 205 peopleInterventions
Paper
Diabetes, Obesity & Metabolism18 Sep
Effectiveness, Safety and Pharmacokinetics of BGM0504, a Dual GLP-1/GIP Receptor Agonist, in Chinese Adults With Overweight or Obesity Without Diabetes: A Phase 2 Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial
Randomised trial in 120 peopleOverweight
Paper
Diabetes, Obesity & Metabolism9 Sep
Safety, Pharmacokinetics and Pharmacodynamics of the GLP-1/GIP/GCG Receptor Agonist UBT251 Injection: A Randomized, Placebo-Controlled Phase 1a/1b Study
Randomised trial in peopleInterventions
Paper
Cancer Treatment and Research Communications24 Aug
Burden and future trajectory of pancreatic cancer in the EU-28, 1990-2023: A GBD 2023 analysis with projections to 2050
Computational studyPopulations
Paper

ADA Scientific Sessions 2026 Abstract6 Jun
UBT251, a Triple Hormone Receptor Agonist in Adults with Overweight or Obesity: A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 2 Trial
Trial in peopleInterventions
Paper
ADA Scientific Sessions 2025 Abstract13 Jun
Efficacy and Safety of BGM0504 in Chinese Patients with Obesity—A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial
Trial in peopleInterventions
Paper